Back to today’s briefing

Story perspectives

Moderna and Merck’s intismeran hits Phase 3 melanoma endpoints

8/22/2026

38 7 Full Breakdown

Summary

Moderna, Merck Triumph

Moderna and Merck announced that intismeran autogene met primary Phase 3 endpoints in melanoma.
The trial enrolled 1,137 high-risk melanoma patients who received surgery then Keytruda alone or with up to nine vaccine doses.
Combination therapy reduced five-year recurrence risk by 49% and metastasis risk by 59%.
Moderna’s shares rose to $174.38 before closing at $133.32.
Merck’s shares climbed from $135.18 to $149.25.

Summary

Merck-Moderna Split

Merck and Moderna will split vaccine profits 50/50.
Analysts forecast intismeran could generate $2 billion in melanoma and $5.6 billion across solid tumors.
Per-patient manufacturing costs for the personalized vaccine are expected to exceed standard biologics.
The renal-cell carcinoma Phase 2 study will read out its first results in April 2027.
Investors say the partnership revives confidence after Moderna’s shares fell below $30 in 2025.

Summary

Personalized mRNA Success

Personalized mRNA vaccine required six to eight weeks to manufacture and succeeded in about 85% of participants.
French oncologist Suzette Delaloge called the approach “real hope” and noted extensive French participation.
The vaccine can target up to 34 tumor-specific antigens identified from a patient’s DNA sample.
Experts stress the treatment is not preventive and aims to stop recurrence after surgery.

1 of 3

Moderna, Merck Triumph

Moderna and Merck announced that intismeran autogene met primary Phase 3 endpoints in melanoma.
The trial enrolled 1,137 high-risk melanoma patients who received surgery then Keytruda alone or with up to nine vaccine doses.
Combination therapy reduced five-year recurrence risk by 49% and metastasis risk by 59%.
Moderna’s shares rose to $174.38 before closing at $133.32.
Merck’s shares climbed from $135.18 to $149.25.

1 / 3